• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Kinetics of hemagglutination-inhibition antibodies following maternal influenza vaccination in HIV-infected and HIV-uninfected women-infant dyads

tetano

Editor, Senior Moderator
J Infect Dis. 2015 Jun 16. pii: jiv339. [Epub ahead of print]
[h=1]Kinetics of hemagglutination-inhibition antibodies following maternal influenza vaccination in HIV-infected and HIV-uninfected women-infant dyads.[/h] Nunes MC[SUP]1[/SUP], Cutland CL[SUP]1[/SUP], Dighero B[SUP]2[/SUP], Bate J[SUP]2[/SUP], Jones S[SUP]1[/SUP], Hugo A[SUP]1[/SUP], van Niekerk N[SUP]1[/SUP], Kuwanda L[SUP]1[/SUP], Izu A[SUP]1[/SUP], Weinberg A[SUP]2[/SUP], Madhi SA[SUP]3[/SUP]; Matflu Team.
[h=3]Collaborators (8)[/h]

[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h]  We evaluated the immunogenicity of trivalent inactivated influenza vaccine (IIV3) in HIV-infected and uninfected pregnant women and the persistence of hemagglutination-inhibition (HAI) antibodies in mothers and infants.
[h=4]METHODS:[/h]   Antibodies were measured pre-vaccination, one month post-vaccination, at delivery and 24 weeks post-partum in mothers and within one week of birth and at 8, 16 and 24 weeks of age in infants.
[h=4]RESULTS:[/h]   We enrolled 98 HIV-uninfected and 100 HIV-infected pregnant women including 93% with ≥200 CD4+ cells/?L. Compared with HIV-uninfected, HIV-infected women had lower seroconversion rates (63%-92% vs. 36%-40%), lower antibody titers through 24 weeks post-partum, and overlapping antibody half-lives (106-121 vs. 87-153 days). Infant titers were lower than the maternal titers within one week of delivery regardless of vaccine strain and HIV-exposure status. Compared with HIV-unexposed, HIV-exposed infants had similar transplacental influenza-antibody transfer ratio; lower titers and frequency of titers ≥1:40 (82%-95% vs. 43%-79%) at birth; and higher antibody half-lives (43-45 vs. 56-65 days).
[h=4]CONCLUSIONS:[/h]   Compared with HIV-uninfected, HIV-infected pregnant women had lower antibody responses and persistence thereof. Compared with HIV-unexposed, HIV-exposed infants had lower antibodies at birth, but similar after 8 weeks of life. Early IIV3 administration during pregnancy did not decrease infant birth antibody titers.
? The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.


PMID: 26080370 [PubMed - as supplied by publisher]
 
Back
Top Bottom